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In solution antimony exists either in the pentavalent or trivalent oxidation state. As Sb(III) is more toxic
than Sb(V), it is important to be able to perform a quantitative speciation analysis of Sb’s oxidation
state. The most commonly applied chromatographic methods used for this redox speciation analysis
do, however, often show a low chromatographic Sb recovery when samples of environmental or
biological origin are analysed. In this study we explored basal chemistry of antimony and found that
formation of macromolecules, presumably oligomeric and polymeric Sb(V) species, is the primary cause
of low chromatographic recoveries. A combination of HPLC-ICP-MS, AFFF-ICP-MS and spin-
filtration was applied for analysis of model compounds and biological samples. Quantitative
chromatographic Sb redox speciation analysis was possible by acidic hydrolysis of the antimony
polymers prior to analysis. Sample treatment procedures were studied and the optimum solution was
acidic hydrolysis by 1 M HCl in the presence of chelating ligands (EDTA, citrate), which stabilise the
trivalent oxidation state of Sb.
Introduction
In aqueous solution, antimony exists either in the pentavalent or
trivalent oxidation state. Sb(III) is considered more toxic than
Sb(V);1 therefore it is important to be able to perform a complete
quantitative redox speciation analysis. The determination of
Sb(III) and Sb(V) in aqueous solution is most commonly per-
formed by separation by anion-exchange chromatography
(AEC) followed by element specific detection.2,3 Separation of
aqueous Sb(V) and Sb(III) is typically achieved on a strong AEC
column, using a mobile phase of pH 4.0–5.5 containing chelating
ligands, such as EDTA, phthalic acid or tartrate.
The importance of complexing ligands in the mobile phase for
AEC was established by Lintschinger et al.,4 who also showed
that adding a strong competing anion, e.g. phthalate, to the
EDTA mobile phase improved the chromatographic system by
shifting the Sb(III) peak to a shorter retention time and improving
its symmetry. A complexing mobile phase serves to preserve the
trivalent oxidation state of Sb during the chromatographic
separation, as Sb(III) easily oxidizes to Sb(V) in aqueous solu-
tions.5 Moreover, in most cases Sb(III) is irreversibly retained on
the AEC columns when chelators are not present in the mobile
phase.4,6 It should be noted that Sb(III) species also have been
reported to be retained irreversibly on reversed phase columns.7
As the AEC method using a combination of EDTA and
phthalic acid in the mobile phase appears to be the most
successful approach for determination of Sb oxidation state so
far, it has been extensively applied.3 Sb(III)–citrate, Sb(III)–
tartrate and SbCl3 all elute at the same retention time due to the
mobile phase’s conversion of all complexes into an Sb(III)–EDTA
complex.4,8 Lintchinger et al. pointed out the importance of this
effect when performing redox speciation analysis on real world
samples, in order to avoid Sb(III) hiding in peaks of unknown
identity.4 However, EDTA does not chelate Sb(V), as
Sb(V)–citrate and Sb(OH)6
 elute at different retention times
(as demonstrated in Fig. 1, mobile phase A) at the applied
concentrations and pH values.8,9 Hence, the lacking ability to
convert Sb(V) complexes into one common complex partly
explains the numerous reports of unidentified peaks even in
studies where the EDTA–phthalic acid mobile phase was
used.8,10–12 For the purpose of oxidation state determination, the
elution of various Sb complexes is a limitation. Likewise it has
been pointed out that the proximity of the Sb(OH)6
 peak to the
void elution makes identification of this Sb species less reliable.13
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chromatograms showing the effect of acid pretreatment on PentostamTM,
adenosine-Sb(V) and cell extract when using the mobile phase of 20 mM
EDTA and 2 mM phthalic acid (Figure Si, Sii and Siv, resp.), and on
adenosine-Sb(V) when using the 100 mM citrate mobile phase
(Figure Siii). See DOI: 10.1039/c0an00796j
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This was clearly illustrated by Hansen and Pergantis in a study
where the peak eluting at the retention time of Sb(OH)6
 upon
further analysis revealed to consist of not less than five different
Sb species.6
The AEC method based on the EDTA–phthalic acid mobile
phase typically gives an Sb recovery of 100% when applied for
analysis of water samples or standard solutions. However, it is
notable that the chromatographic recovery is often not complete
when analysing extracts of biological and environmental
samples. Krachler and Emons reported a chromatographic
recovery of 51–78% when analysing Sb in urine.14 Hansen and
Pergantis had a recovery of 73% for Sb(V) spiked to yoghurt.6
Zheng et al. calculated a recovery of 60% when analysing
aqueous extracts of particulate matter;9 in a recent study Cane-
pari et al. had recoveries of 10–70% for similar extracts and
attributed it to the presence of antimony nanoparticles.10 When
de Gregori et al. speciated Sb in different marine algae, the
recoveries varied between 18 and 93%.15 In most studies,
however, the chromatographic recovery is not reported.
Sb(V) can chelate to a-hydroxy carboxylic acids16 and to
vicinal hydroxy groups;17,18 such multidentate bindings seem to
explain the polymeric nature of the Sb(V) based drug sodium
stibogluconate (Pentostam).19 Likewise, the drug meglumine
antimonate is oligomeric due to chelation by vicinal hydroxy
functions.20 Several types of organic Sb(V) polymers are
described where Sb is bound via oxygen atoms in a non-chelate
fashion, e.g. as ether or ester bonds.21 Carraher and Blaxall
reported that the synthesis of Sb(V)-polyesters from alkylated Sb
halides and organic diacids happens rapidly already at room
temperature.22 Also Sb(III) polymer formation has been described
with organic polyhydroxy compounds.23 Sb(V) is a well known
catalyst of esterification24 and an initiator of cationic polymeri-
sation.25 Sb(III) is extensively used as a polycondensation catalyst
in the production of poly(ethylene terephthalate), where it
promotes esterification and transesterification.26 Thus, antimony
both forms polymers with organic molecules and catalyses
polymerisation reactions.
The association between antimony and polymers made us
hypothesise that the widespread problems with low chromato-
graphic recoveries of Sb in extracts of biological samples are due
to incorporation of Sb in polymers, which do not elute from the
High Performance Liquid Chromatography (HPLC) columns.
The aims of this study were to: (1) document the formation of
polymers between Sb and biological molecules in dilute solutions
(mM level), (2) document their corruption of chromatographic
HPLC recoveries and (3) develop a procedure for liberating the
Sb from the polymers in order to make Sb redox speciation
analysis possible. As a simple model of a biological sample,
a solution of Sb(V) incubated with an excess of ascorbic acid was
used. Ascorbic acid is known to oxidise to a variety of compo-
nents with alcohol, aldehyde, ketone and carboxylic acid func-
tional groups.27 Thus, if Sb is capable of forming polymers with
molecules with multiple –OH functional groups in aqueous
solutions at low temperatures, polymers are expected in this
solution. Ascorbic acid is also able to reduce Sb(V) to Sb(III),28 so
both oxidation states will be available for polymerisation reac-
tions. Other samples either known to contain oligomeric Sb
species (Pentostam) or to have Sb(V) chelates (Sb(V)–adenosine
and Sb(V)–citrate) were also analysed. Finally, the optimised
procedure for Sb redox speciation analysis was tested on extracts
of leukocyte cells incubated with Sb (the experiments are sum-
marised in Table 1).
Experimental
Chemicals and reagents
Antimony(III) chloride, citric acid monohydrate, acetic acid,
ascorbic acid, ammonia (28%), dimethyl sulfoxide (DMSO) and
sodium dodecyl sulfate were from Merck (Darmstadt, Ger-
many); potassium hexahydroxoantimonate, phthalic acid,
diammonium EDTA and tetraethylammonium hydroxide (40%)
were from Fluka (Buchs, Switzerland); ammonium formate and
ammonium acetate were from Riedel-de Ha€en (Seelze, Ger-
many); diammonium citrate, adenosine ($99%) and formic acid
were from Sigma-Aldrich (Steinheim, Germany); hydrochloric
acid (30%) was form VWR International (Fontenay-sous-Bois,
France); and sodium stibogluconate (Pentostam) was from
GlaxoSmithKline (Barnard Castle, UK). The water used
throughout the study was Millipore deionised water (18.2 MU
Fig. 1 Comparison of HPLC-ICP-MS chromatograms achieved with mobile phase A (20 mM EDTA, 2 mM phthalic acid, pH 4.5) and B (100 mM
citrate, pH 4.5). The most likely identity of the eluted species is stated. The void elution is approx. at 1.3 minutes (determined by injecting Li+); i.e. 13 s
prior to the Sb(OH)6
 peak with mobile phase A. In mobile phase A, Sb(III) elutes as the EDTA complex regardless whether SbCl3, Sb(III)–tartrate or
Sb(III)–citrate is injected, whereas Sb(V)(OH)6
 and Sb(V)–citrate elute at different retention times. In mobile phase B both oxidation states elute as
citrate complexes.
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cm) from a Milli-Q Plus Ultra-pure water system from Millipore
(Bedford, USA). All reagents were of analytical grade.
Mobile phases: (A) a mixture of 20 mM (NH4)2EDTA and 2
mM phthalic acid or (B) 100 mM citric acid, both of pH 4.5
(adjusted with ammonia).
Sb(V) stock solution (12.0 mM) was prepared by dissolving
potassium hexahydroxoantimonate in water. A Sb(III) stock
solution (50.0 mM) was prepared by dissolving SbCl3 in DMSO.
Ascorbic acid–Sb mixtures of 10 mM KSb(OH)6 or SbCl3 and
100 mM ascorbic acid were prepared in a 180 mM ammonium
acetate buffer at pH 5.0 and incubated for five days at 37 C
following at least eight days incubation at room temperature. No
precipitation or opaqueness of the solution, which would indi-
cate the presence of particles, was observed. Adenosine–Sb(V)
mixture of 10 mM KSb(OH)6 and 10 mM adenosine was
prepared in water; the mixture was allowed to stand for at least
1½ h prior to use to allow Sb(V)–adenosine complexes to form.
For sample pretreatment, citrate was used as a 4 M stock solu-
tion, (NH4)2EDTA as a 300 mM stock solution, and (NH4)2–
citrate as a 2.67 M stock solution. The acidic sample pretreat-
ment was made by adding 30% HCl to a final concentration of 1
M, together with EDTA stock solution to 30 mM and where
appropriate, citric acid stock solution to 100 mM. The amount of
sample was chosen so the Sb concentration in the pretreatment
mixtures was 2 mM, except from the cell extract where it was 665
nM. The pretreatment was performed for minimum 2 h unless
otherwise stated. Neutralisation was best performed with the
(NH4)2-citrate stock solution. Non-acid treated samples were
prepared in concentrations of 500 nM. Of the samples containing
1 M HCl, 2.5 ml were injected for HPLC analysis; for other
samples 10 ml were injected.
Cell cultivation
Leukocyte cell extracts were prepared from a human leukocyte
cell line (ACC 124), cultured as previously described.29 The cells
were seeded at 0.15 millions per ml in medium with Pentostam
added (to 10 mg Sb per litre). After 4 days the cells were har-
vested by centrifugation, washed twice by resuspension in Hank’s
buffered salt solution (Invitrogen, Paisley, UK), resuspended in
50 ml water, lysed with 100 ml 1% w/v sodium dodecyl sulfate and
then frozen. The extract was filtered through a 0.45 mm syringe
filter prior to use.
Ultrafiltration
Ultrafiltration of Pentostam, the ascorbic acid–Sb(V) mixture
and KSb(OH)6 solution was performed in spin filters (Vivaspin
500, Sartorius Stedim Biotech, G€ottingen, Germany) with a 3
kDa molecular weight cut-off membrane (polyethersulfone). The
Sb solutions were diluted to 1 mM in 100 mM ammonium
formate, pH 3.5, prior to filtration. The filters were centrifuged at
14 100  g for 8 minutes. For total Sb mass balance determi-
nation the amount of sample applied, the amount of filtrate, and
the amount of the retained solution were determined by weight.
Instrumentation
HPLC-ICP-MS. A Hamilton PRP-X100 AEC column (150 
4.1 mm; 5 mm; Hamilton Company, Reno, NV, USA) with
a guard column was used in combination with an Agilent 1100
HPLC system with an autosampler (Agilent Technologies, Santa
Clara, CA, USA). The mobile phase flow rate was 1 ml min1. A
PE-SCIEX ELAN 6000 Inductively Coupled Plasma-Mass
Spectrometer (ICP-MS) (Perkin-Elmer, Norwalk, CT, USA)
with a PC3 cyclonic spray chamber (Elemental Scientific Inc.,
Omaha, NE, USA) was used with a MicroMist glass concentric
nebulizer (Glass Expansion, Romainmo^iter, Switzerland). Lens
voltage, nebuliser gas flow and rf power were optimised on
a daily basis. Both antimony isotopes, 121Sb and 123Sb, were
measured. Data analysis was performed on a TotalChrom
workstation (Perkin-Elmer).
AFFF-MALS/DLS-ICP-MS. Asymmetrical Flow Field-Flow
Fractionation (AFFF) coupled with Multi-Angle Light Scat-
tering (MALS)-/Dynamic Light Scattering (DLS)- and ICP-MS
was carried out using an Eclipse 3 AFFF system equipped with
a Dawn HELEOS MALS/DLS detector (Wyatt Technology
Table 1 Summary of chromatographic experiments. Concentrations: HCl 1 M; EDTA 30 mM; citric acid (citr.a.) 100 mM. Mobile phase A (mp A) 20
mM EDTA and 2 mM phthalic acid, mobile phase B (mp B) 100 mM citric acid; both at pH 4.5
Sample
HPLC method A HPLC method B
Assumed non-eluted speciesSample preparation
HPLC
recovery (%) Sample preparation
HPLC
recovery (%)
Sb(III) Diluted in mp A 100 Diluted in mp B 100
Sb(V) Diluted in mp A 100 Diluted in mp B 100
16 h in HCl 101  2
Sb(V) + citric acid 16 h in HCl 86.2  1.1 16 h in HCl 100 Sb(V)–(citrate)2
Sb(V) + ascorbic acid 4.5 h in mp A 45.0  1.8 8 h in mp B 41.0  1.8 Oligomers/polymers of Sb(V)
and (oxidised) ascorbic acid3 h in HCl + EDTA 68.6  1.1 8 h in citr.a., HCl and EDTA 71.6  1.4
Pentostam 0 h in mp A 26 Oligomers/polymers of Sb(V)
and gluconic acid3.5 h in mp A 81.0  1.0 3 h in mp B 66
0 h in HCl + EDTA 88
4 h in HCl + EDTA 100.5  0.2 2 h in citr.a., HCl & EDTA 98.0  0.5
Sb(V) + adenosine 5 h in mp A 102  1 2 h in mp B 82.1  0.1 (Oligomers of Sb(V)
and adenosine?)2 h in HCl + EDTA 95.6  0.8
4½ h in HCl + EDTA 102  2 2 h in citr.a, HCl and EDTA 97.5  1.1
Sb(V) + cells 3 h in mp A 66.0  2.0 6 h in mp B 77.4  2.2 Sb(V)-containing
oligomers/polymers3.5 h in HCl + EDTA 93.5  5.1 1, 2, 4 h in citr.a, HCl and EDTA 96.7  1.6
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Europe GmbH, Dernbach, Germany) in combination with an
Agilent 7500ce ICP-MS system (Agilent Technologies). The
injection of samples and delivery of carrier liquid for the AFFF
system were carried out using an Agilent 1200 HPLC pump and
autosampler system. The size of the detected complexes was
estimated with the simulation software Eclipse Chromatogram
(Release 1.0.4; Wyatt Technology Europe) using measured
retention times of detected Sb complexes, AFFF flow rate
settings, and separation channel dimensions as input variables.
During elution the detector flow was set to 0.5 ml min1 and the
cross flow to 1 ml min1. For the separation a 3 kDa molecular
weight cut-off polyethersulfone bottom membrane and a spacer
thickness of 350 mm was used. The channel length was 152 mm,
the channel width 21.5 mm at the injection site and 3 mm at the
channel exit. The membrane moisture expansion was determined
to be 145 mm using the retention time and measured Stokes
diameter for a polystyrene nanosphere with a known size
(Thermo Fisher Scientific, Fremont, CA, USA) using the same
flow conditions as for the Sb samples. These values were used as
input variables for the simulation of particle size of the Sb(III)
and Sb(V) complexes.
Results and discussion
Method optimisation
An obvious approach for depolymerisation of potential Sb-
containing polymers is acid hydrolysis. Treatment with HCl has
previously been used in sample preparation prior to potentio-
metric speciation analysis of meglumine antimonate, so that Sb
could be ‘‘released in the solution’’;30 the role of HCl may likely
have been to hydrolyse the previously mentioned oligomers.
Hence it seemed promising as a sample treatment procedure
prior to chromatography as well. Inclusion of a strong chelating
agent such as citric acid in the hydrolysis mixture to bind Sb
should promote the depolymerisation process, shifting the
chemical equilibrium in favour of depolymerisation. This
strategy was investigated further; however, the initial experi-
ments of treating Sb(V) solutions with HCl together with citric
acid showed an unexpected low chromatographic recovery,
indicating the need for change in the chromatographic proce-
dure. A sample of the Sb(V) standard incubated with 1 M HCl
and 100 mM citric acid overnight had a chromatographic
recovery of only 86.2 (1.1)% when analysed by HPLC-ICP-MS
using a mobile phase of 20 mM EDTA and 2 mM phthalic acid,
pH 4.5 (mobile phase A). A control sample incubated without
citric acid had a recovery of 101 (2)%. The reason for this
observation became obvious when shifting to a mobile phase of
very high eluting strength; 100 mM citric acid at pH 4.5 (mobile
phase B). In this mobile phase, the Sb(V) treated with HCl and
citric acid eluted as two peaks: one at 2.2 minutes and a minor
one at 15.3 minutes (Fig. 1, mobile phase B), together providing
full recovery. The distribution of Sb(V) between the peaks when
using mobile phase B proved time and pH dependent. If Sb(V)
was freshly diluted in the mobile phase prior to injection, no
second peak was observed, but with time the peak accounted for
up to 4% of the Sb. At lower pH values the fraction increased
further; for an Sb(V) sample prepared in 100 mM citrate at pH 0,
about 20% eventually eluted in the second peak. The occurrence
of two peaks can be explained by the formation of two different
citrate complexes. A likely explanation is that the first peak is
a 1 : 1 Sb(V)–citrate complex, and that the second, slower formed
peak is a 1 : 2 complex (both complexes are known to exist8).
Citrate is known as one of the ions with highest eluting
strength in AEC.31 When the second complex was retained for
15.3 minutes even with a mobile phase of 100 mM citrate, it has
obviously strong affinity to the stationary phase—thus it cannot
be expected to elute at all with a weaker eluting mobile phase like
A, in agreement with our observations. Complexes between Sb(V)
and citrate have previously been shown in biological samples,13
and the two different complexes must be expected always to
coexist. The application of mobile phases with too weak elution
strength may thus contribute to the recovery problems experi-
enced when analysing real world samples; therefore, the potential
of using mobile phase B with a high elution strength was inves-
tigated. Fig. 1 compares the chromatograms achieved with the
two mobile phases and shows the most likely nature of the eluted
species: When using mobile phase A Sb(III)–citrate elutes as
Sb(III)–EDTA prior to Sb(V)–citrate. In 100 mM citrate (mobile
phase B) the elution order of Sb(III) and Sb(V) is reversed, which
suggests that here Sb(III) elutes as the actual citrate complex. Like
for Sb(V), the method provides full recovery for Sb(III).
It should be noted that when Sb(V) was diluted in water and
injected for analysis using mobile phase B, a fraction of Sb eluted
in the solvent front presumably unchelated; however, this was
avoided by diluting the sample in the mobile phase instead of
water (even if it was done immediately prior to analysis). When
analysing samples subjected to acid treated using mobile phase B,
unchelated Sb(V) in the solvent front was avoided by including
citric acid in the sample treatment mixture or by adding citrate
after the acid treatment.
Preservation of oxidation state
For redox speciation analysis, it is vital that the sample prepa-
ration procedure does not change the oxidation state of the
species in the sample. As Sb(V) is the thermodynamically fav-
oured oxidation state in aqueous solution under oxic condi-
tions,32 oxidation of Sb(III) is a risk. Sb(III)’s oxidation upon acid
treatment was explored on a solution of SbCl3 instead of
KSb(III)–tartrate (the normally used standard of Sb(III)). The
chelating ability of tartrate protects against oxidation of Sb(III)33
but cannot be considered representative for conditions in natural
samples. A 2 mM solution of SbCl3 was prepared with HCl (1 M)
and citric acid (100 mM); after 3 h a slight oxidation of Sb(III)
was observed (4.9%). However, addition of 10 mM EDTA
decreased the oxidation to 2.3% and of 30 mM EDTA to 1.7%
(higher EDTA concentrations were not useable due to EDTA
precipitation). Based on these results the sample treatment
procedure chosen for further experiments was for mobile phase
A: 1 M HCl and 30 mM EDTA, and for mobile phase B: 1 M
HCl, 100 mM citric acid and 30 mM EDTA.
In spite of the low pH of the treated samples, direct injection
without neutralisation was considered acceptable as the PRP-
X100 column has a working range down to pH 1. However, we
observed that oxidation was provoked if the acidified samples
were repeatedly exposed to the stainless steel injector needle.
When injecting only once from each vial the degree of oxidation
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was negligible. Alternatively, the acidic sample can be neutralised
prior to injection. However, neutralisation with ammonia,
ammonium formate or tetraethylammonium hydroxide was
found to cause severe oxidation. In contrast, diammonium
hydrogen citrate was found useful as only 2.0% oxidation was
observed 2 h after neutralisation (performed on an SbCl3 solu-
tion incubated 4.5 h with 1 M HCl and 10 mM EDTA prior to
the neutralisation).
To summarise, as long as the acidic sample’s exposure to
stainless steel is kept to a minimum, or if neutralisation is done
with citrate as base, the oxidation associated with the acidic
sample preparation is very limited.
Analysis of ascorbic acid–Sb(V)
With mobile phase A, the ascorbic acid–Sb(V) mixture displayed
poor chromatographic behaviour as obvious from Fig. 2 (I).
When the sample was diluted in mobile phase A prior to analysis,
a chromatographic recovery of only 45.0 (1.8)% was achieved.
If the sample was prepared in 1 M HCl and 30 mM EDTA the
peak shape improved (Fig. 2, II), and so did the recovery, which
became 68.6 (1.1)%. Some unidentified species render a small
peak at 2.2 and 7.4 minutes.
When the ascorbic acid–Sb(V) mixture was diluted in and
analysed by means of mobile phase B, the chromatographic
recovery was found to be only 41.0 (1.8)% (Fig. 3, I). However,
treatment with 1 M HCl, 100 mM citrate and 30 mM EDTA
rendered a recovery of 71.6 (1.4)% and a much improved peak
shape of the main Sb(V) peak (at 2.2 min) (Fig. 3, II). Thus, the
recovery of the acid-treated sample was nearly the same for the
two mobile phases. However, the shape of the analytical peaks
with mobile phase B was much better than with mobile phase A, as
B made practically all Sb elute as peaks of known oxidation state.
The increased recovery using both chromatographic methods,
after hydrolysis was due to an increase in Sb(V) solely; hence we
conclude that non-eluted Sb without acid treatment was in
the pentavalent oxidation state. The poor chromatography of the
ascorbic acid–Sb(V) mixture and the improvement of recovery and
peak shape by HCl treatment substantiate the theory of Sb being
released from macromolecules after hydrolysis with acid. To test
this hypothesis we applied ultrafiltration and field flow fraction-
ation-ICP-MS in order to prove the presence of Sb-containing
polymers in the ascorbic acid–Sb(V) mixture.
Ultrafiltration of an ascorbic acid–Sb(V) mixture revealed that
8% of the total Sb was bound in macromolecules with a molec-
ular mass above 3 kDa. For Pentostam 20% of the antimony was
in a form unable to pass the filter. As a negative control, a solu-
tion of KSb(OH)6 (1.00 mM) was ultrafiltrated with no decrease
in Sb concentration. These findings are in agreement with
previous reports of Sb-containing polymers in Pentostam19,20 and
suggest that polymers also have been formed in the ascorbic
acid–Sb(V) mixture. (The fraction of Sb in the Sb-ascorbic acid
mixture unrecoverable from the HPLC column when not treated
with acid is much more than 8%, showing that the unrecoverable
Sb species also include some that are less than 3 kDa molecular
weight.)
Analysis of ascorbic acid–Sb(V) and ascorbic acid–Sb(III)
mixtures by AFFF-MALS/DLS-ICP-MS showed that Sb was
associated with macromolecules larger than the pores of AFFF
bottom membrane (3 kDa molecular weight cut-off was used),
and only these larger particles would have passed through the
AFFF cell to the ICP-MS. The particles did give rise to a single
peak corresponding to Sb (121Sb) recorded by ICP-MS. The
concentration of the complexes was, however, not large enough
to generate any useful light scattering signal for direct size
determination; hence the particle size was estimated by simula-
tion. The estimated Stokes diameter for the Sb(III) and Sb(V)
complexes was around 3 nm. Particles of this size would indeed
be retained in the carrier liquid inside the AFFF flow cell, as only
particles much below 1 nm in diameter would be lost by passage
through the 3 kDa cut-off of the AFFF bottom membrane. The
experiments confirmed that Sb-containing macromolecules with
a Stokes diameter of approximately 3 nm were present in the
sample solutions, thus confirming and detailing the results
obtained by ultracentrifugation.
Analysis of Pentostam
As stated, Pentostam is known to contain polymers of Sb(V) and
gluconic acid. A sample of Pentostam freshly diluted with mobile
Fig. 2 HPLC-ICP-MS chromatogram of an ascorbic acid–Sb(V)
mixture 4½ h after dilution in the mobile phase (I) or after 3 h treatment
with 1 M HCl and 30 mM EDTA (II). Mobile phase: 20 mM EDTA and
2 mM phthalic acid at pH 4.5 (A).
Fig. 3 HPLC-ICP-MS chromatogram of an ascorbic acid–Sb(V)
mixture 8 h after dilution in the mobile phase (I) or after 8½ h treatment
with 1 M HCl, 100 mM citric acid and 30 mM EDTA (II). Mobile phase:
100 mM citrate, pH 4.5 (B).
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phase A displayed an ill resolved chromatogram with a recovery
of only 26%, using mobile phase A. Upon standing for 3½ h the
recovery improved to 81.0 (1.0)%, but still the chromatogram
contained two unidentified peaks. Sample pretreatment with 1 M
HCl and 30 mM EDTA for approx. 4 h increased the recovery to
100.5 (0.2)%, but a small shoulder on the main Sb(V) peak was
present (ESI, Fig. Si†).
Fig. 4 (I) shows the chromatogram of Pentostam with mobile
phase B, diluted 3 h previously in mobile phase B. At least three
unidentified peaks are visible, and the recovery was only 66%.
Treatment with HCl removed the unidentified peaks (Fig. 4, II)
and improved the recovery to 98.0 (0.5)%. Fig. 4 (I) highlights
an advantage of mobile phase B compared to A, namely that the
elution of Sb(V) is well separated from the solvent front, at 2.2
min as opposed to 1.5 min (i.e. only 13 s after the solvent front in
our system). Therefore with mobile phase B, unidentified peaks
near the solvent front are not likely to be mistaken for the Sb(V)
(potentially leading to false conclusions on the redox speciation
of the sample) but are recognised as unknown.
These results show that sample treatment with HCl signifi-
cantly improves the recovery for Pentostam with both mobile
phases A and B. This may be of interest beyond the level of
a model system for biological samples. Franco et al. reported up
to 15.4% of the toxic Sb(III) in the Sb(V) drug sodium stibo-
gluconate by titration with iodine combined with differential
pulse polarography.34 A chromatographic method for determi-
nation of the redox speciation of this drug could be of significant
clinical importance, since it provides a more convenient method
for control of Sb(V) pharmaceutics.
Adenosine–Sb(V) mixture
In HPLC methods for redox speciation analysis it is desirable to
elute all analytes in peaks of known oxidation state. As discussed
above, treatment with HCl and citric acid neatly removed any
unidentified peaks in the chromatogram of Pentostam. To explore
the removal of unidentified peaks further, a mixture of adenosine
and Sb(V) was analysed. Sb(V) is known to form complexes with
molecules containing a ribose moiety such as ribonucleosides.18
Such complexes may potentially be present in Sb(V)-containing
biological samples and may not elute with the same retention time
as unbound Sb(V), potentially leading to unidentified peaks in
chromatograms based on mobile phase A. This was the case when
analysing a mixture of adenosine and Sb(V), which showed
a broad peak at 5.6 minute besides the normal Sb(V) peak, when
mobile phase A was used. HCl treatment was not able to remove
the unknown peak, which made up 12–14% of the antimony
(ESI, Fig. Sii†). Next, the chromatographic analysis utilising
mobile phase B was tested. When the sample was diluted in mobile
phase B prior to analysis (2 h) no unknown peaks were visible and
the recovery was 82.1 (0.1)%. If HCl treatment was used (2 h),
the recovery increased to 97.5 (1.1)% (ESI, Fig. Siii†). Thus, the
latter procedure was preferable.
Cell extract
It has so far been demonstrated that HCl treatment and the use
of mobile phase B greatly improve the chromatography of the
simulated biological samples. To test if this also holds true for
a real biological sample, we analysed an extract of human
leukocyte cells grown in medium with Pentostam added. The
chromatogram of the cell extract analysed with mobile phase A
had a chromatographic recovery of 66.0 (2.0)% and displayed
an unidentified peak immediately after (and incompletely
resolved from) the Sb(V) peak (ESI, Fig. Siv, I†).
With mobile phase B the cell extract had a chromatographic
recovery of 77.4 (2.2)% (Fig. 5, I). The recovery was determined
ca. 2 and 6 h after dilution in mobile phase B and did not increase
during this time span. The chromatogram showed baseline
resolution, but there was an unidentified peak at the solvent front
(1.4 minute). Treatment with HCl increased the recovery to 96.7
(1.6)% (whether the treatment was for 1, 2 or 4 h had no
obvious influence). The chromatogram did not contain any
unknown peaks (Fig. 5, II). It is interesting to note that the eluted
amount of Sb(III) relative to the total amount of Sb (determined
by direct injection) is the same before and after the acid treat-
ment; 31.1 (1.3)% before (n ¼ 3) vs. 30.9 (0.9)% after (n ¼ 6).
This suggests that the Sb not eluted of the column, thereby
causing incomplete recovery before acid treatment, is in the
pentavalent oxidation state. It also confirms that the acid treat-
ment causes no significant oxidation of Sb(III) in the sample.
Fig. 4 HPLC-ICP-MS chromatogram of Pentostam 3 h after dilution in
the mobile phase (I) or after 2 h treatment with 1 M HCl, 100 mM citric
acid and 30 mM EDTA (II). Mobile phase: 100 mM citrate, pH 4.5 (B).
Fig. 5 HPLC-ICP-MS chromatogram of a cell extract diluted in the
mobile phase (6 h after dilution, I); or treated with 1 M HCl and 100 mM
citrate for 2 h (II). Mobile phase: 100 mM citrate, pH 4.5 (B). (Sb(V)
elutes in two peaks as discussed in the section on optimisation of the
chromatographic method.)
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Conclusion
Our experiments strongly indicate the formation of polymers
between Sb and biological molecules in dilute solutions, and that
these corrupt the chromatographic HPLC recoveries of such
samples. Treatment with 1 M HCl greatly improved the recovery
and shape of chromatograms of both simulated and real bio-
logical samples. In all samples it was Sb(V) that was recovered. As
Sb(III) is stable/not oxidised during our methodology it can be
concluded that the macromolecules causing low recoveries con-
tained Sb(V). Likewise, replacement of the classical EDTA/
phthalic acid mobile phase (A) with citrate (B) improves peak
shape and chromatographic recovery. Citrate will ensure high
elution strength, avoiding compounds sticking permanently to
the column material. At the same time, excess citrate will
substitute ligands otherwise binding to antimony, resulting in
chromatograms with a maximum of three antimony peaks (one
for Sb(III) and two for Sb(V)). In the case of Pentostam, acid
treatment alone gave full recovery even with mobile phase A, so
for relatively simple matrices the acid treatment alone may be
sufficient for achieving a satisfactory chromatography. In
conclusion, our goal of developing an improved method for Sb
redox speciation analysis in biological samples was achieved.
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